Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Roche Diagnostics Launches EZH2 Mutations Test for Eisai’s Tazverik in Japan
September 7, 2021
- CureApp Files Therapeutic App for Hypertension in Japan, Eyes Launch in 2022
September 6, 2021
- Sunovion Grants European Rights for Kynmobi to BIAL
September 6, 2021
- Takeda Grabs Approval for Zejula Tablet Form
September 6, 2021
- Japan Pharma Officials Relieved by Exit of Suga, Hardliner on Industry
September 6, 2021
- Medipal Now Biggest Shareholder of Nichi-Iko
September 6, 2021
- Ono Chief, Honjo Remain Divided over Opdivo Royalty in Direct Face-Off
September 3, 2021
- Kissei Grants China Rights for Linzagolix to Bio Genuine
September 3, 2021
- Sumitomo Dainippon to Open Office in Vietnam
September 3, 2021
- Viatris Takes Over 14 Off-Patent Drugs, 4 AGs from Pfizer
September 3, 2021
- Reed Maurer, First Japan Representative for PhRMA, Dies at 83
September 3, 2021
- Takeda’s Pevonedistat Misses Primary Goal in PIII for MDS, MML, AML
September 3, 2021
- Astellas Pauses AT132 Gene Therapy Trial after Serious Adverse Event
September 2, 2021
- Kyowa to Resume Alfacalcidol Shipments in Mid-Sept.; MHLW Urges Priority for Patients without Alternative Therapies
September 2, 2021
- Takeda Recalling Suspended Batches of Moderna Jabs in Japan; Administrative Action Possible
September 2, 2021
- MSD Urges Govt to Start HPV Vaccine Discussions as Soon as Possible
September 2, 2021
- SymBio, Singapore’s National Cancer Centre Tie Up to Investigate Brincidofovir’s Anti-Tumor Activity
September 2, 2021
- Former Novartis Japan Chair Masao Torii Tapped as Fronteo’s Strategic Advisor
September 2, 2021
- NanoCarrier’s Otitis Media Treatment Smashes Primary Endpoints in Japan PIII
September 2, 2021
- Kyowa Kirin Files Automated-Injection Device of G-Lasta in Japan
September 2, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…